Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Pan, Xiao Na ^a   Chen, Jia Jie ^a   Wang, Le Xun ^a   Xiao, Ruo Zhi ^a   Liu, Ling Ling ^a   Fang, Zhi Gang ^a   Liu, Quentin ^a   Long, Zi Jie ^a   Lin, Dong Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYTOTOXIC AGENT; MYC PROTEIN; RETINOIC ACID; SHORT HAIRPIN RNA; 5-(4-ETHYLBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE; ANTINEOPLASTIC AGENT; CEBPB PROTEIN, HUMAN; MYC PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOGENETICS; DOWN REGULATION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL PROLIFERATION; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; K562 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; PROTO-ONCOGENE PROTEINS C-MYC; THIAZOLES; TRETINOIN;

EID: 84922356652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105381     Document Type: Article

References (38)

1. Funato T, Harigae H, Abe S, Sasaki T (2004) Assessment of drug resistance in acute myeloid leukemia. Expert Rev Mol Diagn 4: 705-713. (Pubitemid 39220843)
2. Estey EH (2013) Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 88: 318-327.
3. Nielsen DL (2004) Mechanisms and functional aspects of multidrug resistance in Ehrlich ascites tumour cells. Dan Med Bull 51: 393-414.
4. Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, et al. (2011) Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol 38: 911-919.
5. Zeng DF, Zhang J, Zhu LD, Kong PY, Li JP, et al. (2014) Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology. Eur Rev Med Pharmacol Sci 18: 537-543.
6. Liu LL, Long ZJ, Wang LX, Zheng FM, Fang ZG, et al. (2013) Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism. Mol Cancer Res 11: 1326-1336.
7. Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, et al. (2013) Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther 12: 2581-2590.
8. Wong RS, Cheong SK (2012) Leukaemic stem cells: drug resistance, metastasis and therapeutic implications. Malays J Pathol 34: 77-88.
9. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, et al. (2013) mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 18: 726-739.
10. Sheth A, Escobar-Alvarez S, Gardner J, Ran L, Heaney ML, et al. (2014) Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis 5: e1152.
11. Gomez-Casares MT, Garcia-Alegria E, Lopez-Jorge CE, Ferrandiz N, Blanco R, et al. (2013) MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). Oncogene 32: 2239-2246.
12. Singh AM, Dalton S (2009) The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell 5: 141-149.
13. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA (2002) The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21: 3414-3421. (Pubitemid 34587713)
14. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, et al. (2006) The c-Myc target gene network. Semin Cancer Biol 16: 253-264. (Pubitemid 44311039)
15. Field JK, Spandidos DA (1990) The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). Anticancer Res 10: 1-22. (Pubitemid 20155704)
16. Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Leon J (2013) MYC oncogene in myeloid neoplasias. Clin Transl Oncol 15: 87-94.
17. Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE (1996) Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 73: 610-614. (Pubitemid 26068864)
18. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL (2003) Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs 14: 39-47. (Pubitemid 36177353)
19. Tsai WB, Aiba I, Long Y, Lin HK, Feun L, et al. (2012) Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res 72: 2622-2633.
20. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, et al. (1999) Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 5: 2588-2595. (Pubitemid 29437346)
21. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE (2007) Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 18: 161-170.
22. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE (2006) A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 34: 1480-1489. (Pubitemid 44548118)
23. Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, et al. (2013) RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res 73: 6816-6827.
24. Nair R, Roden DL, Teo WS, McFarland A, Junankar S, et al. (2013) c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene.
25. Magri L, Gacias M, Wu M, Swiss VA, Janssen WG, et al. (2014) c-Mycdependent transcriptional regulation of cell cycle and nucleosomal histones during oligodendrocyte differentiation. Neuroscience.
26. Yu L, Zhang YD, Zhou J, Yao DM, Li X (2013) Identification of target genes of transcription factor CEBPB in acute promyelocytic leukemia cells induced by alltrans retinoic acid. Asian Pac J Trop Med 6: 473-480.
27. Follis AV, Hammoudeh DI, Daab AT, Metallo SJ (2009) Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg Med Chem Lett 19: 807-810.
28. Soucek L, Evan GI (2010) The ups and downs of Myc biology. Curr Opin Genet Dev 20: 91-95.
29. Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, et al. (2014) c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123: 1040-1050.
30. Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV (2003) A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci U S A 100: 5313-5318. (Pubitemid 36542702)
31. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, et al. (2003) MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep 4: 575-580. (Pubitemid 36939948)
32. Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, et al. (2011) c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. Mol Cancer Res 9: 1054-1066.
33. Liu L, Wang S, Chen R, Wu Y, Zhang B, et al. (2012) Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun 425: 368-373.
34. Fredlund E, Ringner M, Maris JM, Pahlman S (2008) High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 105: 14094-14099.
35. Mink S, Mutschler B, Weiskirchen R, Bister K, Klempnauer KH (1996) A novel function for Myc: inhibition of C/EBP-dependent gene activation. Proc Natl Acad Sci U S A 93: 6635-6640.
36. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB (1994) c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 13: 4070-4079.
37. Si J, Yu X, Zhang Y, DeWille JW (2010) Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer 9: 92.
38. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, et al. (1998) c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 58: 283-289. (Pubitemid 28047068)